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Abstract The second-generation of direct-acting antiviral agents are the current treatment for 
chronic viral hepatitis C infection. To evaluate the regression of liver fibrosis in patients 
receiving this therapy, liver biopsy remains the most accurate method, but the invasiveness 
of this procedure is its major drawback. Different non-invasive tests have been used to 
study changes in the stage of liver fibrosis in patients with chronic viral hepatitis treated 
with the second-generation of direct-acting antiviral agents: liver stiffness measurements 
(with transient elastography or acoustic radiation force impulse elastography) or different 
scores that use serum markers to calculate a fibrosis score. We prepared a literature review 
of the available data regarding the long-term evolution of liver fibrosis after the treatment 
with direct-acting antiviral agents for chronic viral hepatitis C. 
Keywords  chronic viral hepatitis C, direct-acting antiviral agents, liver fibrosis 
Highlights ✓ Transient elastography is the routine investigation for liver fibrosis monitoring in patients 
with chronic viral hepatitis C treated with direct acting antiviral agents. 
✓ The APRI and FIB-4 scores registered the highest decrease between the baseline and the 
end of the treatment in patients with chronic viral hepatitis C treated with direct acting 
antiviral agents. 
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Introduction 
The main objective in treating chronic viral hepatitis C 
(CHC) with the second-generation of direct-acting 
antiviral agents (DAAs) is to achieve a sustained virologic 
response (SVR). Reversing liver fibrosis in previously 
infected patients is a secondary goal, since achieving viral 
clearance does not reverse all the liver damage. DAAs do 
not have an anti-fibrotic effect (1). In patients who 
achieved SVR with interferon therapy (the previous 
standard of care in CHC), liver fibrosis regression was 
measured in 42% of the cases, while 53.1% of the patients 
did not have a significant change in the liver fibrosis stage, 
and fibrosis progression was reported in 4.6% of the 
patients (2). 
In order to measure liver fibrosis, besides the gold 
standard of liver biopsy, various fibrosis scores calculated 
from routine laboratory tests have been developed and 
validated in recent years. These scores have numerous 
advantages, as they are neither invasive procedures nor 
expensive investigations. The aim of this article is to assess 
the changes that occur in liver fibrosis after SVR is 
achieved with DAAs, measured through liver biopsy and 
different non-invasive tests: transient elastography (TE), 
acoustic radiation force impulse elastography (ARFI), 
fibrosis-4 score (FIB-4), aspartate aminotransferase-
platelet ratio index (APRI), and hyaluronic acid (HA).    
Discussions 
Transient Elastography (TE) 
TE represents a non-invasive method of liver stiffness 
(LS) measurement which is used for fibrosis screening in 
various hepatic disorders as an alternative to liver biopsy 
(3). TE is routinely performed for liver fibrosis assessment 
prior to DAA therapy and also as a follow-up after 
achieving SVR (4-6).  
A cohort study including adults with CHC who 
received DAA-based therapies reports a regression of 
>30% in LS measured by TE 12 months after the end of 
treatment (EOT) (7). Fibrosis regression was demonstrated 
in another study including patients with advanced fibrosis 
(F3-F4), who were monitored by TE at baseline, at EOT, 
and 12 weeks and 24 weeks after EOT (8). There were 
significant differences registered by TE between the 
baseline and EOT (8.3 kPa vs 7.4 kPa), EOT and 24-week 
SVR (7.4 kPa vs 5.3 kPa), and baseline and 48-week SVR 
(8.3 kPa vs 5.4 kPa) (9). 
An improvement of LS was noticed in 82% of the 
patients with SVR at a 2-year follow-up. In 42% of the 
cases, liver fibrosis was decreased by at least 3 kPa (10). 
Facciorusso et al. found an LS decrease from 12.3 kPa to 
6.6 kPa at a 5-year follow-up after DAA therapy (11).  
Another study with a long follow-up period (up to 72 
weeks after EOT) indicated a significant and steady decline 
in LS values. The median LS values were 11.25 kPa before 
the initiation of treatment, 7.8 kPa at EOT, 6.45 kPA at 24 
weeks of SVR, 6.25 kPa at 48 weeks of SVR, and 5.45 kPa 
at 72 weeks of SVR (12). In patients with liver cirrhosis, a 
large decrease in LS was observed, from a 32.5 kPa median 
at baseline to a 21.3 kPa median at EOT (13).  
APRI 
APRI is a simple-to-use liver fibrosis marker, 
calculated by applying the following formula: [Aspartate 
aminotransferase level (ULN)/platelet count (109/L)] ∗100 
(14). The APRI test has a 65.1% sensitivity (Se) and 7l.8% 
specificity (Sp) in detecting F2-F3, and 93.8% Se and 
72.4% Sp in diagnosing liver cirrhosis. An APRI value of 
0.77 differentiates F1 and F2, and a value of 0.84 is the cut-
off between F3 and F4 (14, 15). APRI values decrease in 
CHC patients after treatment with DAAs, even in subjects 
who do not achieve SVR. In patients with SVR, the median 
APRI was lowered from 1.07 to 0.41. In non-SVR patients, 
the median value dropped from 2.05 to 1.13 (5). In another 
study, 48% of the patients had an APRI score higher than 
1 at baseline, but after DAA treatment, only 7.7% had 
APRI values above 1 (16). 
Median APRI values decrease significantly after 24 
weeks of DAA therapy, from 1.4 to 0.5. After this period, 
the APRI stabilizes, and at 96 weeks after EOT no 
significant change is observed (17). Lledó et al. reported 
that the APRI index was decreased at EOT, but there was 
no significant variation in its values at 12-week SVR 
follow-up: 1.47 at baseline, 0.58 at EOT, and 0.54 at SVR 
(18). APRI regression is found in patients with liver 
transplant treated with DAAs (from 2.7±0.3 to 0.4±0.05 at 
12-week SVR). Patients with severe inflammation or liver 
steatosis at baseline have greater improvements in the 
APRI index compared to those with lower inflammation 
and no steatosis (19). In the study conducted by Fabbri et 
al., APRI decreased in hepatitis C/HIV co-infected patients 
who underwent treatment with DAAs from a median of 
0.94 to 0.37 (20). 
Improvements in the APRI score after CHC treatment 
are explained by the normalization of liver enzymes and 
the increase in the number of platelets. Patients with F2-F3 
have an improvement in APRI regardless of their treatment 
response. In patients with cirrhosis, fibrosis regression is 
significantly correlated with achieving SVR (21). In a 
study by Christian et al., the reduction in APRI was found 
Liver fibrosis and direct-acting antiviral agents 
 212 
to be more pronounced in patients with F0-F2 compared to 
F3-F4 (22). 
Tao et al. studied liver fibrosis regression in CHC 
patients infected with the genotype 3 variant of hepatitis C 
virus, treated with 3 different DAA regimens. This 
particular viral genotype has a faster progression of liver 
fibrosis to cirrhosis and shows more resistance to DAAs. A 
significant reduction in APRI was found after different 
DAA treatments, both in respondents (from 1.834 to 0.619, 
p < 0.001) and non-respondents (from 5.026 to 1.248, 
p = 0.002 for relapsed patients) (23). 
Serum markers of liver fibrosis 
Different serum biomarkers have been studied for the 
detection of liver fibrosis.  
Hyaluronic acid (HA) was demonstrated to be useful 
for the detection of liver fibrosis in CHC patients, 
especially in cases where liver biopsy is restricted (such as 
end-stage renal disease) (24, 25). CHC patients who 
responded to treatment with daclatasvir and asunaprevir 
had a lower value of HA at SVR compared to the baseline 
values (123 ± 43 vs. 71 ± 14 ng/mL, p<0.01), while non-
respondents showed no significant difference before and 
after the treatment (145 ± 43 vs. 172 ± 46 ng/mL, p = 
0.465) (26). The Enhanced Liver Fibrosis (ELF) score is an 
algorithm that uses age and serum levels of procollagen 
type III amino terminal propeptide, tissue inhibitor of 
metalloproteinases-1 and HA to give an estimate for liver 
fibrosis. In a sofosbuvir treatment study, the ELF score was 
decreased compared to the baseline (from 10.00 to 9.37, 
p=0.007). Patients treated with sofosbuvir and pegylated 
interferon showed a temporary increase in HA 
measurements at 4 weeks during the treatment (from 59.5 
to 177.9 mg/ml, p=0.002), presumably because of the pro-
inflammatory effect associated with the interferon therapy 
(6). 
FIB-4 
The FIB-4 score has been established alongside other 
non-invasive fibrosis scores in the international guidelines 
for the evaluation of liver fibrosis (15). The Apricot study 
developed a simple test using laboratory measurements to 
predict liver fibrosis in a large cohort of HIV/hepatitis C 
co-infected patients. The results of the study showed that 
age, serum aspartate aminotransferase, international 
normalized ratio, and platelet count were independent 
predictors of fibrosis. These variables were used to obtain 
the following formula: Age (years) × aspartate 
aminotransferase [U/L] / (platelets [109/L] × (alanine 
aminotransferase [U/L])1/2), known today as the FIB‐4 
index (27). In a recent study on a multicenter real-world 
cohort, significant liver fibrosis and cirrhosis were 
predicted with high accuracy by FIB-4 using TE as a 
reference (28). 
FIB-4 has been validated for the evaluation of CHC and 
has acceptable Se and Sp, particularly in advanced fibrosis 
and cirrhosis. FIB-4 shows a significant decrease in all 
patients undergoing DAA treatment, especially in those 
achieving SVR (p<0.001) (5). A significant decline in FIB-
4 values is seen from baseline to 24 weeks after SVR 
(p<0.0001) (11).  
Another study proposed that a longer follow‐up period 
could allow detection of LS changes unrelated to the 
decrease in the liver inflammatory activity, but rather 
associated with the improvement in liver architecture and 
function. Giannini et al. followed up 52 CHC patients for a 
median of 60 weeks after successful DAA treatment with 
SVR. FIB‐4 values progressively decreased from baseline 
to the end of the follow‐up period (16). 
ARFI 
ARFI is a novel procedure that enables the assessment 
of liver fibrosis during a conventional ultra-sonographic 
examination. This imaging technique quantifies the 
mechanical properties of tissues, without manual 
compression, by measuring the shear wave velocity 
induced by acoustic radiation and propagation in the liver 
tissue (29). Compared to TE, the elastography technique 
currently used in clinical practice, ARFI showed promising 
results in the assessment of liver fibrosis staging in CHC 
and HIV/hepatitis C co-infected patients (13, 30). Similar 
to other studies on patients with SVR after DAAs, the 
ARFI evaluation found that LS improves in patients with 
cirrhosis. Also, a decrease in LS was detected at 24 weeks 
after SVR by ARFI similar to TE (from 2.04 ± 0.62 m/s at 
baseline to 1.75 ± 0.57 m/s at 24 weeks after SVR) (31). 
Liver biopsy 
The degree of inflammation, the stage of fibrosis, and 
the histological improvement after achieving SVR are still 
best evaluated through liver biopsy (32). In addition to 
these findings, a recent short-term study evaluated 51 
patients who underwent liver biopsies after SVR was 
achieved. Although liver enzymes normalized after 
achieving SVR, significant histological inflammation was 
still present in 16% of the patients (33). 
Jason et al. tried to assess whether TE can be used in 
the management of patients with advanced fibrosis or 
cirrhosis, after achieving SVR, and compared the results to 
liver biopsy. In their study, there was discordance between 
post-SVR fibrosis stages predicted by TE vs. liver biopsy. 
Thus, it is unclear if TE following SVR can predict the 
fibrosis stage as reliably as liver biopsy (34). 
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Conclusions 
TE has become a routine investigation for liver fibrosis 
monitoring in patients receiving treatment with DAAs, 
ARFI being another elastography method that can be used. 
The APRI and FIB-4 scores registered the greatest change 
when measured at EOT, since the platelet count and the 
liver aminotransferase values that make up their formulas 
showed the most significant improvement around that 
point. Serum markers such as HA, tissue inhibitor of 
metalloproteinases-1, and the combined ELF score also 
improve after the treatment with DAAs. 
Acronyms and abbreviations 
APRI – aspartate aminotransferase-platelet ratio index 
ARFI – acoustic radiation force impulse elastography 
CHC – chronic viral hepatitis C 
DAAs – direct-acting antiviral agents  
EOT – end of treatment 
FIB-4 – fibrosis-4 score 
HA – hyaluronic acid 
LS – liver stiffness 
Se – sensitivity 
Sp – specificity 
SVR – sustained virologic response  
TE – transient elastography. 
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